Newron CEO on Xadago and upcoming pipeline milestones

April 12, 2017 Christoph Graener

Newron CEO Stefan Weber discusses the company’s Parkinson’s therapy, Xadago (safinamide), on the eve of its US market approval during the recent BIO-Europe Spring partnering conference. Newron, a clinical-stage biopharma company listed on the Swiss Exchange, is focused on the development of novel therapies for patients with diseases of the central nervous system. As well as Xadago—developed in partnership with Zambon, which holds global marketing rights to the product with the exception of Asia—Newron has three other clinical assets in its pipeline. Its most advanced is sarizotan, a serotonin 1A (5-HT1A) receptor agonist in development for the treatment of orphan disease Rett syndrome.

Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Stefan Weber – CEO, Newron

Previous Article
Chronic constipation device impresses judges in startup competition

usMIMA CEO and co-founder Markus Wilhelms talks to Scrip about the company’s medical device, MowoOT, which ...

Next Article
Partnerships are key for rare disease drug discovery and development

An in-depth interview with Wendy White, Board Chairman of Global Genes, the leading global rare disease pat...